Ophthalmology is the branch of medicine that deals with the anatomy, body structure and diseases of the eyeball. An ophthalmologist is a specialist in clinical and surgical eye issues. In view that ophthalmologist carry out operations on eyes, they’re each surgical and clinical professionals. A mess of illnesses and conditions can be identified from the eye. The ophthalmic drugs market is witnessing widespread boom due to increasing prevalence of eye issues together with diabetic retinopathy and macular degeneration.
How Big is the Global Ophthalmology Drugs & Devices Market?
The Global Ophthalmology Drugs & Devices Market is expected to be around US$ 36.40 Billion by 2028 and will grow at a CAGR of more than 5% in the given forecast period
The major driving factors of Global Ophthalmology Drugs & Devices Market are as follows:
• Rising prevalence of eye disorders
• Increasing aging population
• Rising prevalence of lifestyle related diseases
• Technological modify in drug delivery techniques
The restraining factors of Global Ophthalmology Drugs & Devices Market are as follows:
• Need awareness between people regarding eye disorders
• Patent expiration of blockbuster ophthalmic drugs
• Ventilation pipeline of ophthalmic drugs
• Lack of health insurance in developing countries
The Global Ophthalmology Drugs & Devices Market is segmented on the lines of its type, treatment and regional. Based on type segmentation it covers OTC drugs and Prescription drugs. Treatment is classified into dry eye drugs, retinal drugs, anti inflammatory drugs and anti glaucoma drugs. The Global Ophthalmology Drugs & Devices Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report provides:
1) An overview of the global market for Ophthalmology Drugs & Devices and related technologies.
2) Analyses of global market trends, with data from 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2028.
3) Identifications of new market opportunities and targeted promotional plans for Global Ophthalmology Drugs & Devices Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional markets for Global Ophthalmology Drugs & Devices Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Novartis (Alcon) is the leading player in the global ophthalmic drugs market with a share of about 24% in 2012. Other major players of ophthalmic drugs market include Allergan, Santen, Pfizer, Merck and Roche and others. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
The Global Ophthalmology Drugs & Devices Market has been segmented as below:
By Type Analysis
• OTC drugs
• Prescription drugs
By Treatment Analysis
• Dry eye drugs
• Retinal drugs
• Anti inflammatory drugs
• Anti glaucoma drugs
By Regional Analysis
• North America
• Europe
• Asia-Pacific
• Rest of the World
Reasons to Buy this Report:
1) Obtain the most up to date information available on all Global Ophthalmology Drugs & Devices Market.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of Global Ophthalmology Drugs & Devices Market data.
4) Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our New Reports :-
Asia-Pacific Chromatography Solvents Market
Autologous Stem Cell and Non-Stem Cell Based Therapies Market
1 INTRODUCTION
1.1 KEY TAKE AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 MARKET DYNAMICS
3.3.1 DRIVERS
3.3.1.1 Aging population to propel the need for ophthalmology drugs and devices
3.3.1.2 Increasing prevalence rates of eye diseases is projected to fuel need for ophthalmology products
3.3.1.3 Changing geographical trends and demographics to drive ophthalmology market
3.3.1.4 Increased focus on combination therapies present enormous prospect for ophthalmology drugs
3.3.2 RESTRAINTS
3.3.2.1 Economic slowdown and saturation to inhibit the growth
3.3.2.2 Drying pipeline and major drugs going off-patent to affect the growth
3.3.3 OPPORTUNITIES
3.3.3.1 Intraocular lenses and phacoemulsification devices provide substantial opportunities in emerging markets
3.3.3.2 Untapped emerging markets present significant opportunities
3.4 MARKET SHARE ANALYSIS
3.4.1 OPHTHALMOLOGY SURGICAL DEVICES
3.4.2 OPHTHALMOLOGY DIAGNOSTIC AND MONITORING DEVICES
3.4.3 VISION CARE
3.4.4 OPHTHALMOLOGY DRUGS
4 GLOBAL OPHTHALMOLOGY DEVICES MARKET
4.1 INTRODUCTION
4.2 OPHTHALMIC DIAGNOSTIC & MONITORING EQUIPMENT MARKET
4.2.1 INTRODUCTION
4.2.2 MARKET DYNAMICS
4.2.2.1 Increasing demand for diagnostic procedure will propel market growth
4.2.2.2 Increased risk of ocular diseases due to aging to goad market growth
4.2.2.3 Technical advances increase market penetration of diagnostic devices
4.2.3 OPTICAL COHERENCE TOMOGRAPHY (OCT) SCANNERS
4.2.4 OPHTHALMIC ULTRASOUND IMAGING SYSTEMS
4.2.5 FUNDUS CAMERA
4.2.6 OPHTHALMOSCOPES
4.2.7 RETINOSCOPE
4.2.8 WAVEFRONT ABERROMETERS
4.2.9 CORNEAL TOPOGHAPHERS
4.2.10 AUTOREFRACTORS/PHOROPTER
4.2.11 PACHYMETER
4.2.12 KERATOMETERS
4.2.13 SPECULAR MICROSCOPE
4.2.14 BIOMETERS
4.2.15 PERIMETERS/VISUAL FIELD ANALYSERS
4.2.16 TONOMETERS
4.2.17 SLIT LAMPS
4.2.18 OTHERS
4.3 OPHTHALMOLOGY SURGERY DEVICES MARKET
4.3.1 CATARACT SURGERY DEVICES
4.3.1.1 Drivers
4.3.1.1.1 Large pool of cataract patients impetus for growth of ophthalmic surgeries
4.3.1.1.2 Phacoemulsification technique to register highest growth in emerging countries
4.3.1.1.3 Multifocal ability of premium lenses creates major growth prospects for ophthalmic market
4.3.1.2 Intraocular Lens (IOL)
4.3.1.3 Ophthalmic Viscoelastic Devices (OVD)
4.3.1.4 Phacoemulsification Devices
4.3.2 GLAUCOMA SURGERY DEVICES
4.3.2.1 Drivers
4.3.2.1.1 Increase in glaucoma susceptible population to drive the surgery devices market
4.3.2.1.2 Increasing prevalence of obesity and diabetes resulting in rise of ophthalmic disorders
4.3.2.1.3 Low compliance with pharmaceuticals to propel the devices market
4.3.2.2 Restraint
4.3.2.2.1 Low awareness to hinder the growth of glaucoma surgical devices market
4.3.2.3 Glaucoma Drainage Devices (GDD)
4.3.2.4 Stents and Implants
4.3.2.5 Glaucoma Lasers
4.3.2.6 Glaucoma Systems
4.3.3 REFRACTIVE SURGERY DEVICES
4.3.3.1 Driver
4.3.3.1.1 High prevalence rates of refractive errors drive the refractive surgeries market
4.3.3.2 Restraint
4.3.3.2.1 No insurance coverage for refractive surgeries restrains the devices market
4.3.3.3 Excimer Laser
4.3.3.4 YAG Laser
4.3.3.5 Microkeratome
4.3.3.6 Femtosecond Laser
4.3.4 VITREORETINAL SURGERY DEVICES
4.3.4.1 Drivers
4.3.4.1.1 Increase in diabetic retinopathies increases demand for vitreoretinal surgeries
4.3.4.1.2 Rising prevalence of age-related macular degeneration (AMD) results in more vitreoretinal surgeries
4.3.4.2 Vitrectomy Machines
4.3.4.3 Photocoagulation Lasers
4.3.4.4 Illumination devices
4.4 VISION CARE
4.4.1 CONTACT LENS
4.4.2 SPECTACLES
5 GLOBAL OPHTHALMOLOGY DRUG MARKET
5.1 INTRODUCTION
5.2 DRUG DELIVERY TYPES
5.2.1 CAPSULES & TABLETS
5.2.2 GELS
5.2.3 EYE DROPS
5.2.4 EYE OINTMENTS
5.2.5 EYE SOLUTIONS
5.3 GLAUCOMA
5.3.1 EXISTING
5.3.1.1 Xalatan (Latanoprost)/Xalacom (Latanoprost and Timolol combination) (Xalabrands)
5.3.1.2 Lumigan franchise [Lumigan (Bimatoprost) + Ganfort (Bimatoprost and Timolol combination)]
5.3.1.3 Tapros/Taflotan (Tafluprost)
5.3.1.4 Saflutan/Zioptan (Tafluprost)
5.3.1.5 Alphagan (Brimonidine)/Combigan (Brimonidine and Timolol combination)
5.3.1.6 Cosopt (Dorzolamide and Timolol combination)/ Trusopt (Dorzolamide)
5.3.1.7 Azarga (Brinzolamide and Timolol combination)
5.3.1.8 Azopt (Brinzolamide)
5.3.2 PIPELINE
5.3.2.1 Brinzolamide & Brimonidine tartrate combination
5.3.2.2 DE-111 (Tafluprost & Timolol maleate combination)
5.4 RETINAL DISORDER
5.4.1 EXISTING
5.4.1.1 Lucentis (Ranibizumab)
5.4.1.2 Visudyne (Verteporfin)
5.4.1.3 Avastin (Bevacizumab)
5.4.1.4 Eylea (Aflibercept)
5.4.2 PIPELINE
5.4.2.1 DE-102 (Betamethasone)
5.4.2.2 Ocriplasmin (Microplasmin)
5.5 DRY EYE
5.5.1 EXISTING
5.5.1.1 Restasis (Cyclosporine)
5.5.1.2 Hyalein (Sodium hyaluronate)
5.5.1.3 Diquas (Diquafosol sodium)
5.5.2 PIPELINE
5.5.2.1 Cyclokat (Cyclosporine)
5.5.2.2 SAR1118 (Lifitegrast)
5.6 ALLERGIC CONJUNCTIVITIS, INFLAMMATION AND CONJUNCTIVITIS
5.6.1 EXISTING
5.6.1.1 Patanol/Pataday/Opatanol (Olopatadine)
5.6.1.2 Bepreve (Bepotastine besilate)
5.6.1.3 TobraDex (Tobramycin & Dexamethasone combination)
5.6.1.4 Xibrom/Bromday (Bromfenac)
5.6.1.5 Vigamox (Moxifloxacin)
5.6.1.6 AzaSite (Azithromycin)
5.6.2 PIPELINE
5.6.2.1 Prolensa (Bromfenac)
5.6.2.2 DE-109 (Sirolimus)
5.6.2.3 Vekacia
6 GEOGRAPHIC ANALYSIS
6.1 INTRODUCTION
6.2 NORTH AMERICA
6.3 EUROPE
6.4 ASIA-PACIFIC
6.5 REST OF THE WORLD (ROW)
7 COMPETITIVE LANDSCAPE
7.1 INTRODUCTION
7.2 MERGERS & ACQUISITIONS
7.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, JOINT VENTURES
7.4 NEW PRODUCT LAUNCH
7.5 APPROVALS
7.6 CLINICAL PIPELINE
7.7 EXPANSION
7.8 OTHER DEVELOPMENTS
8 COMPANY PROFILES
8.1 ABBOTT LABORATORIES
8.1.1 OVERVIEW
8.1.2 FINANCIALS
8.1.3 PRODUCTS & SERVICES
8.1.4 STRATEGY
8.1.5 DEVELOPMENTS
8.2 ALCON, INC.
8.2.1 OVERVIEW
8.2.2 FINANCIALS
8.2.3 PRODUCTS & SERVICES
8.2.4 STRATEGY
8.2.5 DEVELOPMENTS
8.3 ALLERGAN, INC.
8.3.1 OVERVIEW
8.3.2 FINANCIALS
8.3.3 PRODUCTS & SERVICES
8.3.4 STRATEGY
8.3.5 DEVELOPMENTS
8.4 BAUSCH & LOMB, INC.
8.4.1 OVERVIEW
8.4.2 FINANCIALS
8.4.3 PRODUCTS & SERVICES
8.4.4 STRATEGY
8.4.5 DEVELOPMENTS
8.5 CARL ZEISS MEDITEC AG
8.5.1 OVERVIEW
8.5.2 FINANCIALS
8.5.3 PRODUCTS & SERVICES
8.5.4 STRATEGY
8.5.5 DEVELOPMENTS
8.6 ELLEX MEDICAL LASERS LIMITED
8.6.1 OVERVIEW
8.6.2 FINANCIALS
8.6.3 PRODUCTS & SERVICES
8.6.4 STRATEGY
8.6.5 DEVELOPMENTS
8.7 ESSILOR INTERNATIONAL S.A.
8.7.1 OVERVIEW
8.7.2 FINANCIALS
8.7.3 PRODUCTS & SERVICES
8.7.4 STRATEGY
8.7.5 DEVELOPMENTS
8.8 HOYA CORPORATION
8.8.1 OVERVIEW
8.8.2 FINANCIALS
8.8.3 PRODUCTS & SERVICES
8.8.4 STRATEGY
8.8.5 DEVELOPMENTS
8.9 IRIDEX CORPORATION
8.9.1 OVERVIEW
8.9.2 FINANCIALS
8.9.3 PRODUCTS & SERVICES
8.9.4 STRATEGY
8.9.5 DEVELOPMENTS
8.10 JOHNSON & JOHNSON
8.10.1 OVERVIEW
8.10.2 FINANCIALS
8.10.3 PRODUCTS & SERVICES
8.10.4 STRATEGY
8.10.5 DEVELOPMENTS
8.11 MERCK & CO., INC.
8.11.1 OVERVIEW
8.11.2 FINANCIALS
8.11.3 PRODUCTS & SERVICES
8.11.4 STRATEGY
8.11.5 DEVELOPMENTS
8.12 NIDEK CO., LIMITED
8.12.1 OVERVIEW
8.12.2 FINANCIALS
8.12.3 PRODUCTS & SERVICES
8.12.4 STRATEGY
8.12.5 DEVELOPMENTS
8.13 NOVAGALI PHARMA S.A.
8.13.1 OVERVIEW
8.13.2 FINANCIALS
8.13.3 PRODUCTS & SERVICES
8.13.4 STRATEGY
8.13.5 DEVELOPMENTS
8.14 NOVARTIS AG
8.14.1 OVERVIEW
8.14.2 FINANCIALS
8.14.3 PRODUCTS & SERVICES
8.14.4 STRATEGY
8.14.5 DEVELOPMENTS
8.15 PFIZER, INC.
8.15.1 OVERVIEW
8.15.2 FINANCIALS
8.15.3 PRODUCTS & SERVICES
8.15.4 STRATEGY
8.15.5 DEVELOPMENTS
8.16 ROCHE HOLDING AG
8.16.1 OVERVIEW
8.16.2 FINANCIALS
8.16.3 PRODUCTS & SERVICES
8.16.4 STRATEGY
8.16.5 DEVELOPMENTS
8.17 SANTEN PHARMACEUTICAL CO., LTD.
8.17.1 OVERVIEW
8.17.2 FINANCIALS
8.17.3 PRODUCTS & SERVICES
8.17.4 STRATEGY
8.17.5 DEVELOPMENTS
8.18 STAAR SURGICAL COMPANY
8.18.1 OVERVIEW
8.18.2 FINANCIALS
8.18.3 PRODUCTS & SERVICES
8.18.4 STRATEGY
8.18.5 DEVELOPMENTS
8.19 TOPCON CORPORATION
8.19.1 OVERVIEW
8.19.2 FINANCIALS
8.19.3 PRODUCTS & SERVICES
8.19.4 STRATEGY
8.19.5 DEVELOPMENTS
8.20 ZIEMER GROUP HOLDING AG
8.20.1 OVERVIEW
8.20.2 FINANCIALS
8.20.3 PRODUCTS & SERVICES
8.20.4 STRATEGY
8.20.5 DEVELOPMENTS
The Global Ophthalmology Drugs & Devices Market has been segmented as below:
By Type Analysis
• OTC drugs
• Prescription drugs
By Treatment Analysis
• Dry eye drugs
• Retinal drugs
• Anti inflammatory drugs
• Anti glaucoma drugs
By Regional Analysis
• North America
• Europe
• Asia-Pacific
• Rest of the World
SUBSCRIBE TO OUR NEWSLETTERS
